March 14, 2000Circulation
Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty
Why the study?
Does combined abciximab and ticlopidine therapy inhibit arterial thrombosis more effectively than either treatment alone in patients undergoing PTCA?
Population
14 patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
Comparison
Combined abciximab and ticlopidine therapy vs Abciximab therapy alone or ticlopidine therapy…
Design
Cohort
Follow-up
3 days
Authors
Discussion
Loading...
Member takes
Implication
May support extended post-PTCA antithrombotic effects with combination therapy; hypothesis-generating and requires randomized confirmation.
Key Points
- The study aims to assess how combined abciximab and ticlopidine therapy impacts arterial thrombosis and platelet-leukocyte interactions compared to individual treatments.
- Evaluated whole blood samples from 14 patients undergoing PTCA with abciximab, ticlopidine, or both.
- Used a parallel plate flow chamber to measure mural thrombus formation under arterial shear conditions.
- Applied a cone-and-plate viscometer at a shear rate of 3000 s(-1) to assess shear-induced platelet aggregation.
- Combined abciximab/ticlopidine therapy reduced mural thrombus formation to approximately 50% of baseline three days after PTCA.
- Abciximab alone inhibited mural thrombosis for one day post-PTCA, while ticlopidine did not significantly affect thrombus formation.
- Abciximab treatment decreased circulating platelet-neutrophil aggregates but increased P-selectin-mediated leukocyte adhesion.
Structured PICO
Does combined abciximab and ticlopidine therapy inhibit arterial thrombosis more effectively than either treatment alone in patients undergoing PTCA?
P
Population
14 patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
I
Intervention
Combined abciximab and ticlopidine therapy
C
Comparator
Abciximab therapy alone or ticlopidine therapy alone
O
Outcome
Mural thrombus formation under arterial shear conditions and shear-induced platelet aggregationsurrogate
Combined abciximab and ticlopidine therapy provides more prolonged inhibition of mural thrombosis compared to either agent alone in patients undergoing PTCA.
Cite This Study
Fredrickson et al. (2000) studied this question.